Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tysabri
Pharma
Novartis' knockoff of Biogen's Tysabri is first MS biosim in US
The FDA has approved Novartis' Tyruco, a copycat of Biogen's Tysabri, as the first U.S. biosimilar for multiple sclerosis.
Kevin Dunleavy
Aug 25, 2023 11:28am
Reduction of 1,000 jobs will cut Biogen's workforce by 11.5%
Jul 25, 2023 11:05am
Roche takes Biogen to court over royalties for Tysabri
Mar 1, 2023 5:10pm
Novartis angles for approval of Tysabri biosim in Europe, US
Jul 26, 2022 12:21pm
Biogen pays $900M to resolve whistleblower's kickbacks suit
Jul 20, 2022 10:30am
Biogen teams with Happify Health on MS patient support platform
Jul 5, 2022 7:25am
